Condition: Hepatotoxicity · Tenosynovial Giant Cell Tumor · Sponsor: Daiichi Sankyo
A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon optional liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.
This description comes directly from the study's public registry record.
Daiichi Sankyo Contact for Clinical Trial Information · 908-992-6400 · CTRinfo@dsi.com
Always discuss trial participation with your own doctor first.
| Kamalesh K Sankhala MD INC | Santa Monica, California, United States | Recruiting |
| Sarcoma Oncology Research Center LLC | Santa Monica, California, United States | Not Yet Recruiting |
| UCLA Hematology and Oncology | Santa Monica, California, United States | Recruiting |
| The Oncology Institute of Hope and Innovation | Whittier, California, United States | Withdrawn |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Montefiore Medical Center | New York, New York, United States | Withdrawn |
| OSU - James Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
| Kelsey Seybold Clinic - Pearland | Houston, Texas, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04635111